Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, ...

Vertex Pharmaceuticals should have big winners with pain drug Journavx and two promising pipeline candidates. Summit ...

Biotech investors are preparing for what may be the most important clinical trial readout for them this summer.

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of ...

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

Applied Digital has a huge growth opportunity with the explosion in demand for data centers. IonQ is a pioneer in the ...

A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures ...

Recent findings regarding interferon and Janus kinase inhibition may hold clues to improving outcomes in patients with ...